Soligenix, Inc. (NASDAQ:SNGX – Free Report) – Investment analysts at Zacks Small Cap upped their Q3 2023 EPS estimates for Soligenix in a research report issued to clients and investors on Thursday, August 24th. Zacks Small Cap analyst D. Bautz now forecasts that the biopharmaceutical company will earn ($0.44) per share for the quarter, up from their previous forecast of ($0.54). The consensus estimate for Soligenix’s current full-year earnings is ($1.56) per share. Zacks Small Cap also issued estimates for Soligenix’s Q4 2023 earnings at ($0.47) EPS and FY2023 earnings at ($1.56) EPS.
Separately, Alliance Global Partners reduced their price objective on shares of Soligenix from $3.75 to $3.00 in a research note on Monday, June 5th.
Soligenix Trading Up 0.2 %
Shares of NASDAQ SNGX opened at $0.47 on Monday. The company has a quick ratio of 0.94, a current ratio of 2.34 and a debt-to-equity ratio of 0.36. The firm’s 50-day moving average is $0.62 and its two-hundred day moving average is $1.45. Soligenix has a 12-month low of $0.42 and a 12-month high of $13.50.
Institutional Investors Weigh In On Soligenix
Large investors have recently made changes to their positions in the business. Renaissance Technologies LLC lifted its position in Soligenix by 45.5% in the 2nd quarter. Renaissance Technologies LLC now owns 52,800 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 16,500 shares during the last quarter. State Street Corp increased its position in shares of Soligenix by 54.0% in the second quarter. State Street Corp now owns 72,964 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 25,594 shares in the last quarter. Finally, Anson Funds Management LP purchased a new position in shares of Soligenix in the second quarter worth approximately $362,000. Institutional investors and hedge funds own 3.34% of the company’s stock.
Soligenix Company Profile
Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer.
Featured Stories
- Five stocks we like better than Soligenix
- How to Invest in Fertilizer
- 2 Stocks to Get You Ready for the Holiday Season
- How to Invest in Insurance Companies: A Guide
- Profit Potential: 5 Undervalued Stocks With High Dividend Yields
- What is the FTSE 100 index?
- MarketBeat Week in Review – 8/21 – 8/25
Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.
